Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial Meeting Abstract
| Authors: | Choueiri, T. K.; Powles, T.; Burotto, M.; Bourlon, M. T.; Zurawski, B.; Oyervides Juárez, V. M.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Hamzaj, A.; Barrios, C. H.; Richardet, M.; Pook, D.; Tomita, Y.; Escudier, B.; Zhang, J.; Simsek, B.; Apolo, A. B.; Motzer, R. J. |
| Abstract Title: | Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S1159 |
| Language: | English |
| ACCESSION: | WOS:000573469102655 |
| DOI: | 10.1016/j.annonc.2020.08.2257 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 696O_PR -- Source: Wos |
